Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Economics
With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offers insight into this next frontier of immunotherapy. In-Vivo CAR Therapies – Global Research and Development Landscape (2025) report explores the accelerating innovation in in-vivo CAR-T (Chimeric Antigen Receptor) technologies and their potential to reshape treatment across oncology, autoimmune diseases, and other complex indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717625155/en/
In Vivo Car T Infographic from Novotech
Traditional ex-vivo CAR-T therapies require extracting a patient's T cells, engineering them in specialized labs, and reinfusing them, a process that is time-intensive, expensive, and logistically complex. These barriers have significantly restricted patient access.
In contrast, in-vivo CAR-T therapies aim to overcome these challenges by engineering T cells directly within the patient's body using delivery technologies such as viral vectors, lipid nanoparticles (LNPs), and advanced mRNA platforms. The result: faster, more scalable, and potentially off-the-shelf treatments that can expand access, reduce costs, and streamline the patient experience.
In-vivo CAR-T platforms are now being explored not only for hematologic malignancies, but also for solid tumors and autoimmune diseases—areas where traditional CAR-T approaches have faced limitations. Emerging delivery innovations and new combination strategies are driving this expansion.
As a result, in-vivo CAR-T therapies are positioned to reshape clinical practice, expanding their applicability across oncology, autoimmune diseases, and beyond.
The report provides key insights for sponsors, investors, and researchers into one of the most transformative areas of next-generation cell therapy. It includes: The technological evolution of CAR platforms and delivery systems.
The expanding global pipeline of in-vivo CAR assets and clinical programs.
Innovations in lipid nanoparticle (LNP) and viral vector delivery strategies.
Commercial and regulatory considerations shaping future adoption.
Opportunities for in-vivo CAR approaches beyond oncology, including autoimmune diseases and fibrosis.
Novotech has an established track record of supporting in-vivo CAR-T programs globally, including conducting the world's first in-vivo CAR clinical trial, highlighting its leadership and deep expertise in advanced therapeutics, including gene and cell therapies. The company has also conducted more than 100 ATMP studies, spanning gene therapies, gene-modified cell therapies, and mRNA products. Novotech is also actively partnering with biotech sponsors advancing in-vivo CAR pipelines.
Download the full whitepaper to explore the key trends and opportunities driving the future of in-vivo CAR-T therapy.
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250717625155/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical announces first patient enrollment in MAGICAL-SV IDE trial, expanding its Coronary Clinical Program across the U.S. and Europe. Business Wire India Concept Medical Inc. , a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA's IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical's mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. Dr. Samin Sharma enrolled the first patient at New York's Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease. 'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouch as a potential alternative for treating small vessels in the U.S.' Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., across coronary and peripheral interventions, underscoring its commitment to bringing innovative therapies to patients worldwide. MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to DES (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months. An international team of renowned cardiologists, Dr. Martin B. Leon (USA) – Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe) will lead the MAGICAL-SV trial. Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for SCB technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.' Prof. Antonio Colombo, who leads the European arm, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.' This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.' The pioneering MAGICAL-SV trial aims to yield strong clinical evidence for sirolimus-coated balloon therapy, supporting Pre-Market Approval (PMA) for MagicTouch SCB in small vessels and potentially redefining CAD treatment. Dr. Manish Doshi, Founder and MD of Concept Medical, said, "MAGICAL-SV marks another step in our mission to redefine vascular care. We're focused on delivering next-generation solutions, helping clinicians achieve better outcomes and give CAD patients a better quality of life." For media inquiries contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
13 hours ago
- Business Upturn
IDFC FIRST Bank Sets a New Benchmark with Credit Cards Offering Interest Rates as Low as 8.5% p.a.
By Business Wire India Published on August 4, 2025, 13:39 IST Business Wire India IDFC FIRST Bank has introduced a new standard in the Indian credit card market by offering interest rates starting from a remarkably low 8.5% per annum (0.71% per month). This customer-centric initiative places the bank at the forefront of affordability in a market where credit card interest rates typically range from 34% to 46.2% p.a. The dynamic Annual Percentage Rates (APRs) are tailored to individual customer credit profiles, ensuring fair and transparent pricing. This pioneering offering is a testament to IDFC FIRST Bank's commitment to providing accessible and value-driven financial solutions. By presenting significantly lower interest rates, the bank aims to ease the financial burden on consumers and encourage responsible credit management. In addition to low interest rates, the Bank offers several customer-friendly features that add meaningful lifestyle enhancements for cardholders. Lifetime-free credit cards for all backgrounds and spending habits: Customers can choose from a wide range of lifetime-free credit cards designed to match different lifestyles. These cards come with no joining or annual fees. For example, the entry-level FIRST Classic and FIRST Millennia Credit Cards offer movie discounts of up to INR 100 every month. For those seeking premium benefits, the FIRST Select and FIRST Wealth Credit Cards include complimentary airport lounge access and low forex markup. The Bank also offers the FIRST WOW! Credit Card, a lifetime-free option backed by a fixed deposit, ideal for first-time credit users with no or low credit scores. Reward Points that never expire: Cardholders can accumulate valuable reward points on their spending without the pressure of a deadline, giving the freedom to redeem them whenever they choose. Interest-free ATM cash withdrawals: IDFC FIRST Bank lets credit cardholders access emergency cash from an ATM without incurring any interest charges for up to 45 days, a feature that provides unparalleled financial flexibility. Dynamic and fair APRs: Interest rates are dynamically assigned based on the customer's credit profile, ensuring a personalized and equitable rate. Globally recognized digital experience: IDFC FIRST Bank Credit Card users can manage every aspect of their card seamlessly through the Bank's mobile app, ranked by Forrester as #1 in India. IDFC FIRST Bank aims to empower its customers with financial products that are not only feature-rich but also transparent and affordable. The introduction of credit cards with interest rates as low as 8.5% p.a. is a significant step in this direction. By building long-term relationships with customers and offering them fair and best-in-class products, the Bank continues to reinforce its 'Customer First' philosophy. This focus on customer value is a core tenet of IDFC FIRST Bank's operations. In line with the Reserve Bank of India's (RBI) guidelines that encourage fair and transparent practices, the bank's clear communication of its dynamic APRs establishes a positive benchmark in the industry. The combination of a highly competitive interest rate and a globally recognized digital platform underscores IDFC FIRST Bank's position as a forward-thinking and customer-focused financial institution. Visit the official website to know more about IDFC FIRST Bank Credit Cards. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
15 hours ago
- Business Upturn
SCDL's 25-Year Journey – Silver Jubilee Celebrations Across India
Symbiosis Centre for Distance Learning (SCDL) is proudly celebrating its 25th anniversary. This celebration marks an important milestone in the institute's journey of delivering quality education to every corner of the country. Business Wire India Symbiosis Centre for Distance Learning (SCDL) is proudly celebrating its 25th anniversary. This celebration marks an important milestone in the institute's journey of delivering quality education to every corner of the country. Over the past two decades and more, SCDL has shaped the careers of lakhs of students, promoted lifelong learning, and opened pathways to a brighter future. As one of India's leading autonomous distance learning institutions, SCDL has educated more than 1 million learners to date and currently engages with a vibrant community of 80,000+ active students. To honor this remarkable legacy, SCDL hosted a series of Silver Jubilee events across major Indian cities. Celebrations were organized in Dubai (May 2), Bengaluru (28 June 2025), Hyderabad (5 July), New Delhi (12 July), and Mumbai (26 July). The central message of the jubilee perfectly aligned with SCDL's mission – 'To make quality education accessible to all, irrespective of geography or background.' A Legacy of Learning and Transformation For 25 years, SCDL has led the way in India's distance education sector. By emphasizing innovation, flexibility, and career-oriented learning , the institute has continuously adapted to meet the changing needs of both fresh graduates and working professionals. Through its wide range of AICTE-approved Post Graduate Diploma and Certificate programs, SCDL has enabled learners to upskill, reskill, and stay relevant in today's competitive job market. The Silver Jubilee celebration was both a tribute to this enduring legacy and a platform to look toward the future of learning . Highlights from the Celebrations 1) Career Growth Seminars The core attraction of the events was the Career Growth Seminars , where renowned speakers shared insights: Ankur Warikoo – Entrepreneur, Author, and Content Creator, offered practical guidance on building a meaningful career in an AI-first world. Dr. Arjun Vaidya – D2C Entrepreneur and Investor, spoke on reinventing oneself in the evolving job market and fostering an entrepreneurial mindset even in traditional roles. Dale Carnegie-certified trainers – conducted impactful sessions on leadership, emotional intelligence, and thriving in high-pressure corporate environments. These seminars emphasized career acceleration, future readiness, and navigating the digital era . 2) HR Roundtable In collaboration with HR Shapers, SCDL organized a Leadership Roundtable on the theme 'Leadership Development and Capability Building – Reskills, Upskills, and Cross Skills.' The session saw participation from senior HR leaders and decision-makers representing EsselWorld, Larsen & Toubro (L&T India), Adani Group, Wadhwa Group, Dentsu Group, Kalpataru Projects International Ltd, Tech Mahindra, Khosla Profiles Pvt. Ltd, Value First Investments, ISS Facility Services India Pvt. Ltd, Orion Technologies, Kotak Mahindra Bank, Spark Capital, Persistent Systems , and many others. The discussions revolved around future-ready leadership, talent development, and strategies for navigating the evolving skill era . 3) Silver Jubilee & Alumni Awards Ceremony The celebration featured a heartfelt short film showcasing SCDL's 25-year journey , highlighting key milestones, technological progress, and inspirational alumni stories. The evening concluded with the SCDL Alumni Awards , where exemplary alumni were honored with a trophy and a silver coin for their leadership and innovation in various fields. Click here to watch a glimpse of SCDL silver jubilee events. Speaking on the occasion, Dr. Swati Mujumdar, Principal Director, S CDL , said, 'It is heart-warming to see so many alumni and corporate professionals together. SCDL's journey—from starting with the Armed Forces to now reaching over 1 million learners across 36 countries—has been truly inspiring. SCDL originated in 1995 from Symbiosis Institute of Management Studies. General Allu Walia suggested to our Founder and Chancellor, Dr. S. B. Mujumdar, that some courses should be launched for defense personnel who could not come to Pune to study. This vision led to SCDL's inception. By 2001, civilians and their children began enrolling. After I returned from the USA in 2003, I took charge of SCDL, when the institute had very few students and minimal technology use. Between 2003–04, we introduced e-learning, computerized programs, online and on-demand exams, which enabled us to reach learners across India.' She added, 'Symbiosis was started by a teacher. When an educational institute is founded by a businessman versus a teacher, there is a huge difference. Today, Symbiosis alumni are present not just across India, but globally.' The Silver Jubilee Spirit The celebration embodied SCDL's philosophy of 'Education for All' . Whether it was a young professional exploring AI, a homemaker upskilling for remote work, or a retired soldier re-entering civilian life—each story reflected SCDL's inclusive vision . Join the Silver Jubilee Batch SCDL invites new learners to be part of its Silver Jubilee batch , continuing its legacy of academic excellence. Special Benefits Join our flagship program and get below benefits: Free Premium Single Course worth INR 10,000 Free Micro Course from Symbiosis Digital Varsity Scholarships available – for EBC (Economically Backward Class) students and Armed Forces personnel Explore Our Courses Contact us for more details – 8792740467 / [email protected] Looking Ahead SCDL is set to redefine learning through tech-enabled platforms, AI-based learning experiences, and industry-integrated programs . The next 25 years promise more innovation, deeper impact, and a stronger commitment to building a skilled India . Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
